AG

Andrew Gengos

Chief Financial Officer and Head of Corporate Development

Terns Pharmaceuticals

Therapeutic Areas

Terns Pharmaceuticals Pipeline

DrugIndicationPhase
TERN-701Chronic Myeloid Leukemia (CML)Phase 1